What is GenePeeks?
GenePeeks operates at the vanguard of the biotechnology sector, specializing in the identification of inherited disease risks through advanced computational modeling. Unlike traditional screening methods, the company's patented technology digitally simulates the genetic interactions of potential parents to generate thousands of Virtual Progeny. This innovative approach allows for the detection of complex disease risks that remain invisible to conventional diagnostic tools. With a leadership team comprised of experts from Princeton University and seasoned executives from the life sciences industry, GenePeeks provides physician-ordered analytics that empower families with actionable insights into their future children's health. The company's market position is bolstered by its commitment to rigorous scientific validation and its focus on high-impact clinical applications.
How much funding has GenePeeks raised?
GenePeeks has raised a total of $38.8M across 5 funding rounds:
Series A
$5.3M
Debt
$3M
Private Equity
$10M
Series B
$16M
Other Financing Round
$4.5M
Series A (2012): $5.3M with participation from Columbus Nova Technology Partners
Debt (2014): $3M led by Horizon Technology
Private Equity (2016): $10M, investors not publicly disclosed
Series B (2017): $16M featuring Alexandria Real Estate Equities, 5AM Ventures, Alta Partners, and Columbus Nova Technology Partners
Other Financing Round (2017): $4.5M backed by Bridge Bank
Key Investors in GenePeeks
Alexandria Real Estate Equities
A prominent real estate investment trust specializing in the development and management of laboratory and office space specifically designed for the life sciences and technology sectors.
5AM Ventures
A venture capital firm dedicated to early-stage life science investments, focusing on building innovative biotech companies that bring transformative therapies to patients.
Alta Partners
A long-standing venture capital firm with a deep specialization in healthcare and life sciences, supporting entrepreneurs in developing impactful biopharma and care delivery solutions.
What's next for GenePeeks?
With the recent influx of capital, GenePeeks is poised to accelerate its clinical laboratory operations and expand the reach of its proprietary analytics platform. The strategic focus will likely shift toward broadening the adoption of its physician-ordered testing services, further integrating its computational tools into standard reproductive healthcare workflows. As the company scales, it will continue to leverage its partnerships with life science-focused investors to navigate the complex regulatory landscape and solidify its status as a leader in the genomics space. Future growth will be driven by the ongoing refinement of its simulation algorithms and the potential for new diagnostic applications in the broader field of hereditary disease prevention.
See full GenePeeks company page
